Biosimilars Related Topics 
STAT
APRIL 4, 2024
WASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less-expensive versions of the blockbuster, the company confirmed. List prices of Humira biosimilars are as much as 85% lower.
STAT
APRIL 15, 2024
The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment, one of the best-selling medicines in the U.S., However, Hyrimoz is jointly marketed with Cordavis, a new subsidiary that CVS created last August specifically to sell any number of biosimilar medicines in the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
APRIL 24, 2024
Two years after biosimilars became available in the U.S., In addition, patients who used biosimilars often did not pay lower out-of-pocket costs than those who were given brand-name biologic medicines. “The whole purpose of biosimilars was to introduce competition into the marketplace and lead the [U.S.]
STAT
MARCH 14, 2024
Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. Editor’s note: A livestream of this event will be embedded below at 1 p.m. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines?
STAT
SEPTEMBER 26, 2023
Biosimilars are no longer a new and untested class of medicines. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings.
STAT
FEBRUARY 14, 2024
It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. Biosimilars are safe and effective treatments referencing biologic drugs. They If they fail to act, the U.S.
STAT
MAY 13, 2024
industry trade group following a dispute over allegations that the company inappropriately marketed a biosimilar medicine. At issue was an anonymous complaint filed in May 2023 by a physician who contended that Sandoz unfairly attempted to promote a biosimilar version of Tysabri for treating multiple sclerosis as an affordable option.
Expert insights. Personalized for you.
336 
Let's personalize your content